| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T87 |
0-88 |
Sentence |
denotes |
Table 1b Laboratory tests for COVID-19 patients during the stage of disease progression. |
| T88 |
89-129 |
Sentence |
denotes |
Laboratory tests Reference value No. (%) |
| T89 |
130-184 |
Sentence |
denotes |
Total (n = 21) Survival (n = 17) Non-survival(n = 4) p |
| T90 |
185-257 |
Sentence |
denotes |
IL-6 (pg/ml) 0.1–2.9 15 (8–79, 19) 12 (4–18, 15) 195 (127–280, 4) <0.001 |
| T91 |
258-320 |
Sentence |
denotes |
CRP (mg/L) <4 20 (7–45, 21) 15 (7–36, 17) 78 (28–134, 4) 0.042 |
| T92 |
321-407 |
Sentence |
denotes |
CD3+ (cells/μl) 805 to 4459 562 (203–939, 19) 680 (303–945, 15) 232 (129–340, 4) 0.062 |
| T93 |
408-494 |
Sentence |
denotes |
CD4+ (cells/μl) 345 to 2350 297 (135–557, 19) 416 (172–557, 15) 168 (108–250, 4) 0.121 |
| T94 |
495-578 |
Sentence |
denotes |
CD8+ (cells/μl) 345 to 2350 166 (50–336, 19) 273 (122–377, 15) 33 (23–135, 4) 0.016 |
| T95 |
579-663 |
Sentence |
denotes |
CD4+/CD8+ ratio 0.96–2.05 1.7 (1.2–3.1, 19) 1.6 (1.3–2.4, 15) 5.0 (2.0–6.2, 4) 0.079 |
| T96 |
664-747 |
Sentence |
denotes |
CD19+ (cells/μl) 240 to 1317 104 (49–174, 19) 104 (49–236, 15) 84 (34–134, 4) 0.650 |
| T97 |
748-838 |
Sentence |
denotes |
CD16+/CD56+ (cells/μl) 210 to 1514 164 (49–252, 19) 168 (106–252, 15) 33 (10–223, 4) 0.124 |
| T98 |
839-944 |
Sentence |
denotes |
P value is compared the group that survived with the group that did not survive by a Mann-Whitney U test. |
| T99 |
945-982 |
Sentence |
denotes |
Data is presented as median (IQR, n). |
